XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Note 8 - Earnings Per Share | 3 Months Ended
--- | ---
Mar. 31, 2024
Notes to Financial Statements |
Earnings Per Share [Text Block] | Note 8 – Earnings per Share Basic net income per share is computed based on the weighted average number of common shares outstanding for each period presented. Diluted net income per share reflects the potential dilution that would have occurred if securities to issue common stock were exercised, converted, or resulted in the issuance of common stock that would have then shared in our earnings. The following table summarizes the earnings and the weighted average number of common shares used in the calculation of basic and diluted earnings per share (in thousands, except for share and per share amounts):
|  | Three Months Ended March 31 |
|  | 2024 |  |  | 2023 |
Basic: |  |  |  |  |  |  |  |
Weighted average common shares outstanding |  |  | 15,350,240 |  |  |  | 15,337,423 |
Net income attributable to National HealthCare Corporation |  | $ | 26,213 |  |  | $ | 11,723 |
Earnings per common share, basic |  | $ | 1.71 |  |  | $ | 0.76 |
Diluted: |  |  |  |  |  |  |  |
Weighted average common shares outstanding |  |  | 15,350,240 |  |  |  | 15,337,423 |
Effects of dilutive instruments |  |  | 154,856 |  |  |  | 18,912 |
Weighted average common shares outstanding |  |  | 15,505,096 |  |  |  | 15,356,335 |
Net income attributable to National HealthCare Corporation |  | $ | 26,213 |  |  | $ | 11,723 |
Earnings per common share, diluted |  | $ | 1.69 |  |  | $ | 0.76 |
For the three months ended March 31, 2024, 245,726 stock options have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect. For the three months ended March 31, 2023, 691,580 stock options have been excluded from the calculation of diluted weighted average shares of common stock outstanding because the inclusion of these securities would have an anti-dilutive effect.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration